RxDoctor Payments Data

Robert Kwon, MD

Ophthalmology · Lawrence, MANPI 1437193844

Payments from drug & device makers

$4,785in general payments, 2019–2025

Across 141 payments — averaging $33.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$2K
  • AbbVie$1K
  • Oyster Point Pharma, Inc.$380
  • Sun Pharmaceutical Industries Inc.$341
  • Bausch & Lomb Americas Inc.$332
  • Alcon$271
  • plus $510 from 11 others

What the payments were for

  • Speaking & faculty fees$1,48831%
  • Food & beverage$3,29769%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,785 in reported general payments places this provider in the 75th percentile of 653 ophthalmology providers in Massachusetts.

See all ophthalmology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$459,808
Medicare patients
1,443
Services billed
4,565

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine115$170,979
XiidraLifitegrast120$164,318
LumiganBimatoprost201$132,453
Prednisolone Acetate632$33,776
Bromfenac Sodium107$23,823
ProlensaBromfenac Sodium67$23,229
Cyclosporine46$19,413
CombiganBrimonidine Tartrate/Timolol39$17,178
Latanoprost987$14,186
Brimonidine Tartrate267$11,634
SimbrinzaBrinzolamide/Brimonidine Tart46$9,531
Alphagan PBrimonidine Tartrate16$8,308
RhopressaNetarsudil Mesylate16$7,890
Timolol Maleate554$6,961
Ofloxacin489$5,255

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$1,053$328,918371 claims
Bausch & Lomb Americas Inc.Xiidra$332$164,318120 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$25$23,22967 claims
AlconSimbrinza$271$9,53146 claims
Aerie Pharmaceuticals, Inc.Rhopressa$119$7,89016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 653 ophthalmology providers in Massachusetts.

Other ophthalmology in Lawrence

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →